The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
TORONTO, Jan. 27, 2026 /CNW/ - Eli Lilly Canada, Inc announced today that Jaypirca ® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available for use as monotherapy for the treatment of ...
DUBLIN--(BUSINESS WIRE)--The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results